IDEXX Laboratories Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über IDEXX Laboratories Inc Unternehmen

IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, dairy and water testing industries. The Company also provides human medical point-of-care and laboratory diagnostics. Its segments include Companion Animal Group (CAG), Water quality products (Water), and Livestock, Poultry and Dairy (LPD). The CAG segment offers diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. Its Water segment provides testing solutions for accurate detection and quantification of various microbiological parameters in water. Its LPD segment provides diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve the quality and safety of milk.

IDEXX Laboratories Inc Informationen



BörsenkürzelIDXX

Name des UnternehmensIDEXX Laboratories Inc

IPO-datumJun 21, 1991

CEOMr. Andrew Emerson

Anzahl der mitarbeiter11000

WertpapierartOrdinary Share

GeschäftsjahresendeJun 21

AddresseOne Idexx Drive

StadtWESTBROOK

BörseNASDAQ Global Select Consolidated

LandUnited States of America

Postleitzahl04092-2041

Telefon12075560300

Websitehttps://www.idexx.com/

BörsenkürzelIDXX

IPO-datumJun 21, 1991

CEOMr. Andrew Emerson

Führungskräfte von IDEXX Laboratories Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Michael Erickson, Ph.D.

Executive Vice President and General Manager, Point of Care Diagnostics and Telemedicine

12.58K

+18.05%

Dr. Sophie V. Vandebroek, Ph.D.

Independent Director

8.69K

+3.11%

Mr. Lawrence D. (Larry) Kingsley

Independent Chairman of the Board

8.23K

+4.39%

Mr. Michael J. Lane

Executive Vice President and General Manager, Global Reference Laboratories, Diagnostic Solutions and Information Technology

7.70K

--

Ms. Sharon E. Underberg

Executive Vice President, General Counsel, Corporate Secretary

6.12K

+3.08%

Mr. Andrew Emerson

Executive Vice President, Chief Executive Officer, Treasurer

3.84K

+60.39%

Mr. Daniel M. (Dan) Junius

Independent Director

3.00K

+9.56%

Mr. Michael Schreck

Executive Vice President and General Manager, Veterinary Software and Services, Corporate Accounts and Customer Experience

1.92K

+112.86%

Mr. Bruce L. Claflin

Independent Director

1.72K

--

Dr. Stuart M. Essig, Ph.D.

Independent Director

1.09K

+31.76%

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Michael Erickson, Ph.D.

Executive Vice President and General Manager, Point of Care Diagnostics and Telemedicine

12.58K

+18.05%

Dr. Sophie V. Vandebroek, Ph.D.

Independent Director

8.69K

+3.11%

Mr. Lawrence D. (Larry) Kingsley

Independent Chairman of the Board

8.23K

+4.39%

Mr. Michael J. Lane

Executive Vice President and General Manager, Global Reference Laboratories, Diagnostic Solutions and Information Technology

7.70K

--

Ms. Sharon E. Underberg

Executive Vice President, General Counsel, Corporate Secretary

6.12K

+3.08%

Mr. Andrew Emerson

Executive Vice President, Chief Executive Officer, Treasurer

3.84K

+60.39%

Umsatzaufteilung

Währung: USDAktualisiert: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

CAG Diagnostics recurring revenue

878.00M

79.14%

IDEXX VetLab consumables

375.11M

33.81%

Reference laboratory diagnostic and consulting services

367.69M

33.14%

Rapid assay products

100.24M

9.04%

CAG Diagnostics capital - instruments

85.85M

7.74%

Andere

-697.43M

-62.86%

Nach RegionUSD

Name

Umsatz

Anteil

United States

717.87M

64.70%

Europe & Middle East & Africa (EMEA) (Region)

233.27M

21.03%

Asia Pacific

89.30M

8.05%

Canada

46.69M

4.21%

Latin America

22.33M

2.01%

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

CAG Diagnostics recurring revenue

878.00M

79.14%

IDEXX VetLab consumables

375.11M

33.81%

Reference laboratory diagnostic and consulting services

367.69M

33.14%

Rapid assay products

100.24M

9.04%

CAG Diagnostics capital - instruments

85.85M

7.74%

Andere

-697.43M

-62.86%

Aktionärsstatistik

Aktualisiert: Tue, Aug 19

Aktionäre

Aktionärstypen

Aktionäre

Anteil

The Vanguard Group, Inc.

12.30%

BlackRock Institutional Trust Company, N.A.

6.63%

State Street Investment Management (US)

4.44%

Fundsmith LLP

3.30%

Geode Capital Management, L.L.C.

3.08%

Andere

70.25%

Aktionäre

Anteil

The Vanguard Group, Inc.

12.30%

BlackRock Institutional Trust Company, N.A.

6.63%

State Street Investment Management (US)

4.44%

Fundsmith LLP

3.30%

Geode Capital Management, L.L.C.

3.08%

Andere

70.25%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

54.15%

Investment Advisor/Hedge Fund

32.38%

Research Firm

3.94%

Pension Fund

2.49%

Bank and Trust

2.04%

Hedge Fund

0.90%

Individual Investor

0.69%

Sovereign Wealth Fund

0.60%

Family Office

0.54%

Andere

2.27%

Institutionelle Beteiligung



Aktualisiert: Wed, Oct 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q3

2278

77.56M

96.93%

-3.76M

2025Q2

2277

79.81M

99.73%

-1.01M

2025Q1

2279

79.02M

98.21%

-512.23K

2024Q4

2242

76.14M

93.59%

-5.30M

2024Q3

2152

77.90M

94.66%

-4.67M

2024Q2

2140

80.09M

96.98%

-924.14K

2024Q1

2154

77.56M

93.40%

-2.57M

2023Q4

2187

77.94M

93.84%

-2.83M

2023Q3

2153

79.23M

95.34%

-677.16K

2023Q2

2157

77.53M

93.40%

-1.56M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

The Vanguard Group, Inc.

9.84M

12.3%

+19.20K

+0.20%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

5.30M

6.63%

-132.86K

-2.44%

Jun 30, 2025

State Street Investment Management (US)

3.55M

4.44%

-95.45K

-2.62%

Jun 30, 2025

Fundsmith LLP

2.64M

3.3%

-9.04K

-0.34%

Jun 30, 2025

Geode Capital Management, L.L.C.

2.46M

3.08%

+54.40K

+2.26%

Jun 30, 2025

Baron Capital Management, Inc.

2.03M

2.54%

-27.16K

-1.32%

Jun 30, 2025

Invesco Capital Management (QQQ Trust)

1.65M

2.06%

-5.80K

-0.35%

Aug 31, 2025

Polen Capital Management, LLC

1.20M

1.49%

+1.12M

+1519.07%

Jun 30, 2025

Principal Global Investors (Equity)

1.13M

1.41%

+1.75K

+0.16%

Jun 30, 2025

William Blair & Company, L.L.C. (Research)

1.08M

1.35%

-10.27K

-0.94%

Jun 30, 2025

Verbundene ETFs



Aktualisiert: Mon, Oct 6

Name

Anteil

ProShares Pet Care ETF

9.54%

iShares U.S. Medical Devices ETF

5.48%

First Trust Water ETF

5.43%

Hennessy Sustainable ETF

3.75%

Nuveen ESG Mid-Cap Growth ETF

3.53%

Adaptive Core ETF

2.75%

Invesco Raymond James SB-1 Equity ETF

2.49%

First Trust S&P 500 Economic Moat Index ETF

2.37%

SPDR S&P Health Care Equipment ETF

2.24%

First Trust NASDAQ-100 Ex-Technology Sector Index Fund

2.19%

ProShares Pet Care ETF

Anteil9.54%

iShares U.S. Medical Devices ETF

Anteil5.48%

First Trust Water ETF

Anteil5.43%

Hennessy Sustainable ETF

Anteil3.75%

Nuveen ESG Mid-Cap Growth ETF

Anteil3.53%

Adaptive Core ETF

Anteil2.75%

Invesco Raymond James SB-1 Equity ETF

Anteil2.49%

First Trust S&P 500 Economic Moat Index ETF

Anteil2.37%

SPDR S&P Health Care Equipment ETF

Anteil2.24%

First Trust NASDAQ-100 Ex-Technology Sector Index Fund

Anteil2.19%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Art

Verhältnis

Keine Daten

Datum

Art

Verhältnis

Keine Daten